Convergent Genomics is a precision medicine company that combines advances in genomics and machine learning to detect cancer early and non-invasively. Convergent is a leader in applying these technologies for use in liquid biopsy from urine. Using genomic data, our products further integrate clinical scenarios and scientific literature to richly contextualize a patient’s specific risk and enable unique data-driven decision-making.
Our Mission: Transforming cancer care through clear and actionable insights.
Location: United States, California, South San Francisco
Employees: 11-50
Founded date: 2015
Investors 2
| Date | Name | Website |
| - | Civilizati... | civilizati... |
| - | Tencent | tenx.tc |
Mentions in press and media 2
| Date | Title | Description | Source |
| 01.05.2023 | Genomic Urine Test Detects Bladder Cancer from DNA Up to 12 ... | Advances in Next-Generation DNA Sequencing and Machine Learning Enable Rapid Analysis of Genetic Mut... | einpresswi... |
| 25.04.2023 | New Studies on Convergent Genomics' Urine Test for Bladder C... | CHICAGO, April 25, 2023 /PRNewswire/ -- Convergent Genomics announced UroAmp, the company's genomic ... | einpresswi... |